HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $55 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Belite Bio (NASDAQ:BLTE) and maintained a $55 price target.
August 10, 2023 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Belite Bio's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $55.
The reiteration of a 'Buy' rating and a maintained price target of $55 by HC Wainwright & Co. indicates a positive outlook for Belite Bio. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100